Inside the world’s biggest vaccine factory, India’s Serum Institute

The Serum Institute of India is a major player in the fight against COVID-19

PUNE, India : The tiny clinking vials supervised by silent PPE-wearing technicians belie the excitement inside the world’s largest vaccine manufacturer, the Serum Institute of India, a major player in the fight against coronavirus.

The firm, founded in 1966 in the western city of Pune, is producing millions of doses of the Covishield vaccine, developed by AstraZeneca and Oxford University, for India and much of the developing world.

Unlike the rival Pfizer-BioNTech vaccine, Covishield can be stored and transported using standard refrigeration.

Copy of 397223-01-02-1611382419613
The tiny clinking vials supervised by silent PPE-wearing technicians belie the excitement inside the world’s largest vaccine manufacturer, the Serum Institute of India, a major player in the fight against coronavirus.Image Credit: AFP
Copy of 397218-01-02-1611382415452
The firm, founded in 1966 in the western city of Pune, is producing millions of doses of the Covishield vaccine, developed by AstraZeneca and Oxford University, for India and much of the developing world.Image Credit: AFP
Copy of 397228-01-02-1611382427434
Unlike the rival Pfizer-BioNTech vaccine, Covishield can be stored and transported using standard refrigeration. It is also significantly cheaper than the vaccines developed by Pfizer or the US firm Moderna, making it better suited for countries with poorer populations and rusty infrastructure.Image Credit: AFP
Copy of 397215-01-02-1611382448658
An employee in protective gear works on an assembly line for manufacturing vials of Covishield, AstraZeneca-Oxford’s Covid-19 coronavirus vaccine at India’s Serum Institute in Pune.Image Credit: AFP

It is also significantly cheaper than the vaccines developed by Pfizer or the US firm Moderna, making it better suited for countries with poorer populations and rusty infrastructure.

Even before the pandemic, the Indian firm was a world leader in vaccines, producing 1.5 billion doses a year and inoculating two out of three children in 170 countries against diseases such as polio, mumps, meningitis and measles.

Copy of 397225-01-02-1611382422490
Even before the pandemic, the Indian firm was a world leader in vaccines, producing 1.5 billion doses a year and inoculating two out of three children in 170 countries against diseases such as polio, mumps, meningitis and measles.Image Credit: AFP
Copy of 397239-01-02-1611382408328
Its journey kicked off on a stud farm, where the firm’s owners, the Poonawalla family, began breeding horses in 1946, before a conversation with a vet sparked the realisation that anti-toxin serum extracted from the animals could be used to make vaccines.Image Credit: AFP
Copy of 397220-01-02-1611382417525
As a result, when the coronavirus pandemic began to sweep across the world, the company, which recorded annual revenues of over $800 million in 2019-20 and is debt-free, was in pole position to reap the rewards.Image Credit: AFP
Copy of 397469-01-02-1611382410771
With Poonawalla vowing to reserve 50 percent of Covishield stocks for the Indian market, New Delhi, which intends to immunise 300 million people by July, is engaging in a bout of vaccine diplomacy, planning to supply 20 million doses to its South Asian neighbours.Image Credit: AFP
Copy of 397213-01-02-1611382446153
The Serum Institute also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.Image Credit: AFP
Copy of 397236-01-02-1611382434911
If all this sounds overwhelming, the firm’s bosses are not worried. “We are used to these kinds of pressures because even in the past there were situations when we were required to step up the production to meet individual countries’ requirements,” Suresh Jadhav, Serum Institute’s executive director, told AFP.Image Credit: AFP

Its journey kicked off on a stud farm, where the firm’s owners, the Poonawalla family, began breeding horses in 1946, before a conversation with a vet sparked the realisation that anti-toxin serum extracted from the animals could be used to make vaccines.

The Serum Institute soon became a market leader thanks to its cheap and effective drugs, which were eagerly sought after by price-conscious governments and consumers, prompting the company to expand at a dizzying rate.

Copy of 397212-01-02-1611382443934
Even a deadly fire at an under-construction building this week failed to dent confidence, with Poonawalla promptly tweeting that “there would be no loss of #COVISHIELD production due to multiple production buildings that I had kept in reserve to deal with such contingencies”.Image Credit: AFP
Copy of 397211-01-02-1611382441511
An employee in protective gear pushes a trolley inside a lab.Image Credit: AFP
Copy of 397238-01-02-1611382405306
A worker prepares to stack boxes containing vials of Covishield, inside a cold storage room.Image Credit: AFP
Copy of 397237-01-02-1611382437671
Employees prepare themselves before getting inside a lab.Image Credit: AFP

Adar Poonawalla, its 40-year-old CEO, has spent nearly a billion dollars in recent years enlarging and improving the sprawling Pune campus.

As a result, when the coronavirus pandemic began to sweep across the world, the company, which recorded annual revenues of over $800 million in 2019-20 and is debt-free, was in pole position to reap the rewards.

‘Used to pressure’

The palm-fringed Pune campus, whose grounds boast horse-shaped topiaries in a playful nod to the firm’s origins, is home to several buildings where vaccines are manufactured and scrutinised for quality before being deposited into sterilised vials and stored for delivery.

Copy of 397217-01-02-1611382413094
Vials of Covishield, AstraZeneca-Oxford’s Covid-19 coronavirus vaccine are pictured inside a lab.Image Credit: AFP
Copy of 397226-01-02-1611382424971
Vials of Covishield, AstraZeneca-Oxford’s Covid-19 coronavirus vaccine are pictured inside a lab.Image Credit: AFP

From Brazil to South Africa, there is no shortage of customers, with governments clamouring to buy Covishield.

With Poonawalla vowing to reserve 50 percent of Covishield stocks for the Indian market, New Delhi, which intends to immunise 300 million people by July, is engaging in a bout of vaccine diplomacy, planning to supply 20 million doses to its South Asian neighbours.

The Serum Institute also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.

If all this sounds overwhelming, the firm’s bosses are not worried.

” We are used to these kinds of pressures because even in the past there were situations when we were required to step up the production to meet individual countries’ requirements,” Suresh Jadhav, Serum Institute’s executive director, told AFP.

Even a deadly fire at an under-construction building this week failed to dent confidence, with Poonawalla promptly tweeting that “there would be no loss of #COVISHIELD production due to multiple production buildings that I had kept in reserve to deal with such contingencies”.

Copy of 397231-01-02-1611382429980
The palm-fringed Pune campus, whose grounds boast horse-shaped topiaries in a playful nod to the firm’s origins, is home to several buildings where vaccines are manufactured and scrutinised for quality before being deposited into sterilised vials and stored for delivery.Image Credit: AFP
Copy of 397235-01-02-1611382432755
A general view of the Serum Institute campus in Pune.Image Credit: AFP
Adar Poonawalla
Adar Poonawalla (pictured), its 40-year-old CEO, has spent nearly a billion dollars in recent years enlarging and improving the sprawling Pune campus.Image Credit: Supplied
Copy of 396624-01-02-1611382439654
The Serum Institute soon became a market leader thanks to its cheap and effective drugs, which were eagerly sought after by price-conscious governments and consumers, prompting the company to expand at a dizzying rate.Image Credit: AFP

The pandemic has transformed Poonawalla’s public profile, from a jet-setting billionaire known for his expensive taste in cars and fine art to a pharma-tycoon applauded for his willingness to take risks and his commitment to affordable vaccines.

Unsurprisingly, the father-of-two has not held back from taking so-called anti-vaxxers to task, including berating US rapper Kanye West for spreading conspiracy theories.

“Though we enjoy your music very much @KanyeWest, your views on #vaccines come across as irresponsible and borderline dangerous, considering the influence you have today and may have in the future; vaccines save lives,” Poonawalla tweeted in July.

AFP

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s